Fmr LLC Has $5.49 Million Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)

Fmr LLC lifted its stake in NewAmsterdam Pharma (NASDAQ:NAMS) by 35.6% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 330,412 shares of the company’s stock after acquiring an additional 86,712 shares during the period. Fmr LLC’s holdings in NewAmsterdam Pharma were worth $5,485,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Banque Cantonale Vaudoise acquired a new position in NewAmsterdam Pharma during the second quarter valued at approximately $38,000. Sei Investments Co. grew its stake in NewAmsterdam Pharma by 49.1% in the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock valued at $472,000 after buying an additional 8,087 shares during the last quarter. Wolverine Asset Management LLC raised its holdings in NewAmsterdam Pharma by 117.7% in the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after acquiring an additional 8,394 shares during the period. TimesSquare Capital Management LLC lifted its position in NewAmsterdam Pharma by 3.7% during the 3rd quarter. TimesSquare Capital Management LLC now owns 255,245 shares of the company’s stock worth $4,237,000 after acquiring an additional 9,160 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its holdings in NewAmsterdam Pharma by 79.9% during the third quarter. GSA Capital Partners LLP now owns 66,402 shares of the company’s stock valued at $1,102,000 after acquiring an additional 29,496 shares during the period. 89.89% of the stock is owned by institutional investors.

Insider Activity

In other news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84. Following the sale, the insider now directly owns 11,778,760 shares in the company, valued at approximately $295,411,300.80. The trade was a 0.28 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 86,803 shares of company stock worth $1,755,307. Company insiders own 19.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NAMS shares. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Scotiabank raised their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research note on Wednesday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $36.20.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $25.09 on Friday. The stock’s 50-day moving average price is $20.40 and its 200 day moving average price is $18.68. NewAmsterdam Pharma has a 12-month low of $9.61 and a 12-month high of $27.29.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.